(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq:BDSI) today announced that the Company will host an Analyst & Investor Day on Thursday, June 3, 2010 from 11:00 AM to 1:00 PM Eastern Time at the Intercontinental New York Barclay hotel in New York City.

Dr. Mark A. Sirgo, President and Chief Executive Officer and Dr. Andrew L. Finn, Executive Vice President of Product Development will host the session. Global experts in pain management and the treatment of opioid dependence with first-hand experience in clinical studies of, as well as prescribing, ONSOLIS (fentanyl buccal soluble film) and buprenorphine will provide insight into the profile and benefits of both drugs. In addition, BDSI will review the status of the clinical development programs and commercial opportunity for BEMA Buprenorphine in pain and opioid dependence.

Experts will include:

Richard Rauck, MD
Executive Director, Center for Clinical Research in Pain
Pain Fellowship Director, Wake Forest University Health Sciences
President, Carolinas Pain Institute
Winston-Salem, NC

Dr. Keith Budd, FRCA, FFPMRCA
Emeritus Consultant in Pain Medicine
Bradford Teaching Hospital Trust
Bradford, UK

Sandra D. Comer, PhD
Professor of Clinical Neurobiology
Columbia University
New York, NY

The event will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, the presentation will be archived. Those interested in attending the event should contact Lena Adams at lena.adams@icrinc.com or Michael Leone at michael.leone@icrinc.com.

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise consists of two products utilizing BDSI’s patented BEMA buccal soluble film technology. ONSOLIS (fentanyl buccal soluble film) was approved by FDA in July 2009 for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licensed to Meda who launched ONSOLIS in the U.S. last October. BDSI’s second pain product in development, BEMA Buprenorphine, just completed Phase 2 clinical development for the treatment of chronic pain, and entering Phase 1 as a higher dose formulation for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA “Triptan”). BDSI’s headquarters is located in Raleigh, North Carolina.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.